Fig. 1

Biodistribution of [⁸⁹Zr]-DFO(0.7)-RW03_IgG, [⁸⁹Zr]-DFO(3.0)-RW03_IgG, [⁸⁹Zr]-DFO(2.9)-RW03_scFv-Fc in HT-29 xenograft BALB/c nu/nu mice. (a) [⁸⁹Zr]-DFO(0.7)-RW03_IgG (0.16 ± 0.02 MBq, 5 ± 0.7 ug) at 24, 48, 96 h p.i., (b) [⁸⁹Zr]-DFO(3.0)-RW03_IgG (0.14 ± 0.03 MBq, 1 ± 0.3 µg) at 24, 48, 96 h p.i., (c) [⁸⁹Zr]-DFO(2.9)-RW03_scFv-Fc (0.085 ± 0.02 MBq, 1 ± 0.2 µg) at 24, 48, and 72 h p.i. The blocked cohort received [⁸⁹Zr]-DFO-RW03_scFv-Fc (0.09 ± 0.02 MBq, 1.0 ± 0.2 µg) and excess RW03_IgG (400 µg). Uptake is expressed as mean percentage injected dose per gram tissue (%ID/g) ± SEM.